hKIS composition and methods of use

Details hKIS composition and methods of use hKIS composition and methods of use

2005-05-12

2008-08-19

Schnizer, Richard (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C424S450000, C424S233100, C435S320100, C623S001110, C604S508000, C536S023500

Reexamination Certificate

active

07414035

ABSTRACT:
Disclosed herein are novel composition and methods for altering the proliferation of a cell. Included are wild-type and mutant hKIS polypeptides along with cyclin kinase inhibitors containing mutations that prevent their inhibition with serine/threonine kinases.

REFERENCES:
patent: 5674192 (1997-10-01), Sahatjian et al.
patent: 5985635 (1999-11-01), Bandman et al.
patent: 6391632 (2002-05-01), Dubensky et al.
patent: WO 95/10623 (1995-04-01), None
Li et al (J. Biol. Chem. 277(13), 11352-11361, 2002).
Miller et al. (FASEB J. 9: 190-199, 1995).
Deonarain (Exp. Opin. Ther. Patents 8(1):53-69, 1998).
Verma et al (Nature 389: 239-242, 1997).
Crystal (Science 270:404-410, 1995).
Pouton et al (Adv. Drug Del. Rev. 46: 187-203, 2001).
Read et al (Adv. Gen. 53:19-46, 2005).
Anderson (Nature 392:25-30, 1998).
Romano et al (Stem Cells 18: 19-39, 2000).
Somia and Verma (Nature Reviews Genetics 1: 91-99, 2000).
Rosenberg et al, Science 287:1751, 2000.
Juengst (BMJ 326: 1410, 2003).
Maucuer et al (J. Biol. Chem. 272(37): 23151-13156, 1997).
Chen et al (J. Clin. Invest. 99(10): 2334-2341, May 1999).
Morisaki et al (Biochem. Biophys. Res. Comm. 240: 386-390, 1997).
Wu et al (Canc. Res. 61: 7325-7332, 2001).
Olive et al (Gene 151(1-2): 81-88, 1994).
Mahairas, G.G., EST database: Accession # AQ024916, submitted Jun. 1998.
Orkin et al., Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, www.nih.gov Dec. 1995.
Verma, M. et al., Gene Therapy: Promises, Problems and Prospects, Nature, vol. 389, Sep. 1997, pp. 239-242.
Eck, S. L. et al., 1996, Ch 5. Gene Based Therapy, Goodman & Gillman's The Pharmacological Basis of Therapeutics. pp. 77-101.
Mahairas, G.G. et al., HS—2183—A2-B07—MF CIT Approved Human Genomic Sperm Library D Homo Sapiens Genomic Clone, database sheet, XP-002125938, Jun. 23, 1998.
Hiller, K. et al., Soars Total Fetus Nb2HF8 9w Homo Sapiens cDNA Clone, database sheet, XP-002125939, Jun. 11, 1997.
Hiller, K. et al., Soars Total Fetus Nb2HF8 9w Homo Sapiens cDNA Clone, database sheet, XP-002125940, Jun. 11, 1997.
Maucuer, A. et al., KIS is a Protein Kinase with and RNA Recognition Motif, The Journal of Biol. Chem., vol. 272, No. 37, Sep. 12, 1997, pp. 23151-23156.
Muller, D. et al., Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexes, Oncogene, 15, pp. 2561-2576, 1997.
Sheaff, R. et al., Cyclin E-CDK2 is a regulator of p27Kip, Genes and Development, 11, pp. 1464-1478, 1997.
Polyak, K. et al., Cloning of p27Kip, a Cyclin-Dependent Kinase Inhibitor and a Potential Mediator of Extracellular Antimitogenic Signals, Cell. vol. 87, pp. 59-66, Jul. 15, 1994.
PCT International Search Report for PCT/US99/18903.
Boehm, M. et al., A Growth Factor-Dependent Nuclear Kinase Phosphorylates p27Kipand Regulates Cell Cycle Progression, The EMBO Journal, vol. 21, No. 13, pp. 3390-3401, 2002.

Affiliated with

Also associated with

Rating

hKIS composition and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with hKIS composition and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and hKIS composition and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3993209